Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIMMER postpartum obesity trial
ChiCTR2200061895Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in obesity (3 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Body weight change at 6 months. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2200061895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061895.